Revagenix is dedicated to creating life-changing antibiotics, providing urgently needed anti-infective medicines to patients globally. We are advancing a focused pipeline designed to treat infections caused by multidrug-resistant organisms. The team-composed of seasoned industry experts, and augmented by a world-class network of strategic collaborators, partners, investors, and advisors-leverages extensive experience in anti-infective research, development, and commercialization.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/05/24 | undisclosed | Series B |
Novo Holdings Tenmile | undisclosed |
